Collecting data on outcomes of stem cell transplants
Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adults: Clinical Outcome and Complications
This study is collecting information from adults who have had stem cell transplants to see what factors affect their recovery and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 2 sites (Hong Kong and 1 other locations) |
| Trial ID | NCT06702111 on ClinicalTrials.gov |
What this trial studies
This study aims to gather baseline and outcome data related to all types of hematopoietic stem cell transplants, including those from bone marrow, peripheral blood, and cord blood. Conducted at Queen Mary Hospital, it focuses on understanding the prognostic factors that influence the outcomes of these transplants. The observational nature of the study allows for the collection of real-world data from adult patients who have undergone allogeneic hematopoietic stem cell transplantation. The findings may help improve future transplant protocols and patient care.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 years or older who have received allogeneic hematopoietic stem cell transplantation.
Not a fit: Patients who are unable to provide informed consent or are not undergoing allogeneic hematopoietic stem cell transplantation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of factors affecting transplant outcomes, leading to improved patient management and treatment strategies.
How similar studies have performed: Other studies have shown success in collecting outcome data for hematopoietic stem cell transplants, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT). Exclusion Criteria: * participant who is unable to give informed consent in a prospective cohort.
Where this trial is running
Hong Kong and 1 other locations
- Department of Medicine, Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
- Queen Mary Hospital, Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Harry HS Gill, MBBS, MD, FRCP, FRCPath — Department of Medicine, the University of Hong Kong
- Study coordinator: Harry HS Gill, MBBS, MD, FRCP, FRCPath
- Email: gillhsh@hku.hk
- Phone: +852 22555859
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.